Date: 02 Feb 2005

Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Sir,

Helisch and co-workers have reported important data on pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours (Eur J Nucl Med Mol Imaging 2004;31:1386–1392). They compared the dosimetry and biodistribution of [86Y-DOTA-d-Phe1-Tyr3]-octreotide (DOTA-TOC) with those of 111In-pentetreotide. They concluded that adequate dosimetry prior to 90Y-DOTA-TOC therapy is mandatory and that dosimetry with both compounds is possible, although dosimetry with 86Y-DOTA-TOC is more adequate. The latter finding is not surprising since 86Y is the almost perfect surrogate for 90Y and since dosimetry with 86Y-DOTA-TOC was defined as the gold standard by the authors.

The authors point out that dosimetry with 86Y-DOTA-TOC is not widely available owing to the limited access to the radionuclide and the elaborate correction algorithm required. Therefore in our opinion the aim should be to find a more widely feasible method for pre-therapeutic o ...

An authors’ reply to this letter is available at http://dx.doi.org/10.1007/s00259-004-1727-2